Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Alvotech

< Previous 1 2 3 4 Next >
Alvotech Announces Increase in Number of Own Shares
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Appoints Interim Chief Quality Officer
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
From Alvotech
Via GlobeNewswire
Tickers ALVO
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Present at the Jefferies 2023 London Healthcare Conference
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Changes to the Leadership Team
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Completes $100 Million Convertible Bond Private Placement
From Alvotech
Via GlobeNewswire
Tickers ALVO
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Alvotech
Via GlobeNewswire
Tickers ALVO JNJ TEVA
Alvotech to Participate in Jefferies Healthcare Conference
From Alvotech
Via GlobeNewswire
Tickers ALVO
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.